Polygenic Score for Clinicopathologic Features and Survival Outcomes in Papillary Thyroid Carcinoma

被引:0
作者
Li, Sophie [1 ,2 ]
Zheng, Guibin [1 ]
Xu, Li [1 ]
Goswami, Maitrayee [1 ]
Zafereo, Mark E. [1 ]
Sherman, Steven I. [3 ]
Li, Guojun [1 ]
Sturgis, Erich M. [4 ]
Wang, Jennifer R. [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, 1515 Holcombe Blvd, Houston, TX 77030 USA
[2] Baylor Coll Med, Sch Med, Houston, TX USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Endocrine Neoplasia & Hormonal Disorders, Houston, TX USA
[4] Baylor Coll Med, Dept Otolaryngol Head & Neck Surg, Houston, TX USA
关键词
BRAF MUTATION; CANCER-RISK; PREVALENCE; VARIANTS; GERMLINE;
D O I
10.1001/jamaoto.2024.3963
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Importance Genome-wide association studies have identified germline variants associated with the development of papillary thyroid carcinoma (PTC) that can be used to construct a polygenic score (PGS). It is important to determine whether patients with higher germline genetic risk, as summarized using PGS, present with more aggressive disease and/or develop worse clinical outcomes. Objective To assess whether germline risk defined by PGS is associated with clinicopathologic features and survival outcomes for patients with PTC. Design, Setting, and Participants This retrospective cohort study included patients with newly diagnosed PTC who presented to The University of Texas MD Anderson Cancer Center for treatment between 1999 and 2014, with a median follow-up of 12 years. Data were analyzed from December 2023 to April 2024. Exposure Germline risk, as defined by PGS. Main Outcomes and Measures Genomic DNA was extracted from buffy coat cells isolated from peripheral blood samples, and genotyping for germline polymorphisms was performed. Germline risk for PTC was estimated with a previously validated PGS calculated from 10 single-nucleotide variations identified through genome-wide association studies. Stage; PTC-specific survival, defined as the time from PTC diagnosis to death caused by PTC; and overall survival, defined as the time from PTC diagnosis to death by any cause, were analyzed. Results A total of 366 patients were included in the study (261 women [71.3%]; mean [SD] age at diagnosis, 44.3 [13.8] years). There was a statistically significant association between higher PGS and multifocality (beta [SE], 0.40 [0.23]; P = .045) and cervical lymph node involvement (N stage) (beta [SE], 0.62 [0.35]; P = .009) at diagnosis. PGS was associated with PTC-specific survival (hazard ratio, 2.66; 95% CI, 1.03-6.85; P = .04), but this association was not independent of age and overall stage. There was not a statistically significant association between PGS and overall survival. Conclusions and Relevance Findings of this cohort study suggest that patients with a higher germline risk of PTC, as estimated by PGS, present with more aggressive clinicopathologic features. These results contribute to the current understanding of inherited risk in PTC and how germline variants could potentially contribute to disease presentation and clinical outcomes.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [41] Prediction of central lymph node metastasis in papillary thyroid microcarcinoma according to clinicopathologic factors and thyroid nodule sonographic features: a case-control study
    Jin, Wen-Xu
    Ye, Dan-Rong
    Sun, Yi-Han
    Zhou, Xiao-Fen
    Wang, Ou-Chen
    Zhang, Xiao-Hua
    Cai, Ye-Feng
    CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3237 - 3243
  • [42] Do aggressive variants of papillary thyroid carcinoma have worse clinical outcome than classic papillary thyroid carcinoma?
    Song, Eyun
    Jeon, Min Ji
    Oh, Hye-Seon
    Han, Minkyu
    Lee, Yu-Mi
    Kim, Tao Yong
    Chung, Ki-Wook
    Kim, Won Bae
    Shong, Young Kee
    Song, Dong Eun
    Kim, Won Gu
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2018, 179 (03) : 135 - 142
  • [43] Predicting disease-specific survival in patients undergoing active surveillance for papillary thyroid carcinoma
    Nielsen, Stanton
    Kuchta, Kristine
    Huang, Grace
    Zuber, Samuel
    Holoubek, Simon
    Karcioglu, Amanda
    Khokar, Amna
    Prinz, Richard
    Moo-Young, Tricia
    WORLD JOURNAL OF SURGERY, 2025, 49 (04) : 1011 - 1021
  • [44] PAPILLARY MICROCARCINOMA IN COMPARISON WITH LARGER PAPILLARY THYROID CARCINOMA IN BRAFV600E MUTATION, CLINICOPATHOLOGICAL FEATURES, AND IMMUNOHISTOCHEMICAL FINDINGS
    Park, Young Joo
    Kim, Young A.
    Lee, You Jin
    Kim, Soon Hui
    Park, So Yeon
    Kim, Kyung Won
    Chung, June Key
    Youn, Yeo Kyu
    Kim, Kwang Hyun
    Park, Do Joon
    Cho, Bo Youn
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2010, 32 (01): : 38 - 45
  • [45] Hyalinizing trabecular tumor and papillary carcinoma of the thyroid
    Zhu Hong
    Qi Ji-ping
    Wang Ying-wei
    Song Yue-jia
    Zhang Zhi-yi
    CHINESE MEDICAL JOURNAL, 2010, 123 (20) : 2832 - 2835
  • [46] Acromegaly and papillary thyroid carcinoma: A case series
    Heidarpour, Maryam
    Rezvanian, Hassan
    Kachuei, Ali
    JOURNAL OF RESEARCH IN MEDICAL SCIENCES, 2019, 24
  • [47] Outcomes of nonsuspicious contralateral nodules with active surveillance after lobectomy in patients with papillary thyroid carcinoma
    Huang, Hui
    Liu, Jie
    Wang, Xiaolei
    Liu, Shaoyan
    FRONTIERS IN ENDOCRINOLOGY, 2022, 13
  • [48] Glucose tolerance status in patients with newly diagnosed papillary thyroid carcinoma
    Aghamohammadzadeh, Nasser
    Haghi, Taghi Fadayi
    Houshyar, Jalil
    Najafipour, Farzad
    IMMUNOPATHOLOGIA PERSA, 2024, 10 (01):
  • [49] BRAF V600E Does Not Predict Aggressive Features of Pediatric Papillary Thyroid Carcinoma
    Givens, Daniel J.
    Buchmann, Luke O.
    Agarwal, Archana M.
    Grimmer, Johannes F.
    Hunt, Jason P.
    LARYNGOSCOPE, 2014, 124 (09) : E389 - E393
  • [50] Correlation between telomerase reverse transcriptase messenger RNA expression and survival of patients with papillary thyroid carcinoma
    Kwon, Jae Hyun
    Yi, Jin Wook
    SURGERY, 2021, 169 (01) : 43 - 49